Seven Types of Scrutiny: A Tangled And Costly Web Ahead For Device Makers
This article was originally published in Clinica
The “scrutiny” procedure of high-risk devices is one of the most controversial points in the new EU medtech regulations. But medtech manufacturers look to be facing not just one but seven types of regulatory scrutiny across the two proposed regulatory texts. Moreover, the different scrutiny procedures could apply cumulatively to some products. Medtech regulatory expert, Gert Bos, explained in a recent interview with Clinica why this matter needs to be addressed urgently
You may also be interested in...
It seems to be game over for anyone who might have been hoping the European Commission would do a U-turn on its decision to use the Italian CND nomenclature as the basis for communication in Eudamed, instead of the well-established GMDN. But GMDN is strong in its resolve to remain a vital global nomenclature service.
2020 is not getting off to a good start for manufacturers needing to comply with the EU’s new Medical Device Regulation on 26 May 2020. The European Commission’s latest document seems to confirm industry’s fears about the ability of the EU’s medtech system to be ready in time.
December 2019 was a big month for far-reaching EU medtech regulatory developments that will have a significant impact on the way and speed of implementation of the Medical Device Regulation.